Warner Chilcott Limited receives FDA approval for DORYX Delayed-Release tablets, 150 mg

Tue. June 24, 2008; Posted: 07:21 AM

Jun 24, 2008 (M2 EQUITYBITES via COMTEX) -- WCRX | Quote | Chart | News | PowerRating -- Warner Chilcott Limited (NasdaqGS:WCRX) declared on 23 June that the speciality pharmaceutical company has received approval from the US Food and Drug Administration (FDA) for a 150mg strength of DORYX (doxycycline hyclate) Delayed-Release Tablets. DORYX Delayed-Release Tablets are a tetracycline-class oral antibiotic indicated for adjunctive treatment of severe acne.

The company stated that the 150mg tablet strength is in addition to the existing DORYX Delayed-Release Tablets franchise of 100mg and 75mg. It will continue to offer DORYX in 75mg and 100mg strengths.

Comments on this story may be sent to admin@m2.com

For full details on Warner Chilcott Ltd Cl A (WCRX) click here. Warner Chilcott Ltd Cl A (WCRX) has Short Term PowerRatings of 6. Details on Warner Chilcott Ltd Cl A (WCRX) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.